Related Experiment Video

Updated: Oct 9, 2025

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.1K

DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity - Commentary

Robert J Fox1, Mar Tintore2

  • 1Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|December 16, 2021
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
07:20

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy

Published on: August 9, 2024

1.4K
Utilizing Transcranial Magnetic Stimulation to Study the Human Neuromuscular System
12:19

Utilizing Transcranial Magnetic Stimulation to Study the Human Neuromuscular System

Published on: January 20, 2012

27.1K

Related Experiment Videos

Last Updated: Oct 9, 2025

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.1K
Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
07:20

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy

Published on: August 9, 2024

1.4K
Utilizing Transcranial Magnetic Stimulation to Study the Human Neuromuscular System
12:19

Utilizing Transcranial Magnetic Stimulation to Study the Human Neuromuscular System

Published on: January 20, 2012

27.1K

Related Concept Videos

Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

12
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
12
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

21
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
21

Articles linked to this work by shared authors, journal, and citation graph.

De-Escalating and Discontinuing Immunotherapies in Patients With NMOSD and MOGAD.

Neurology·2026

Assessing the feasibility, theoretical interest, and observed behaviors of adding genetic data to a patient-reported multiple sclerosis registry.

Multiple sclerosis journal - experimental, translational and clinical·2026

Refining Treatment Monitoring in Patients With Relapsing Multiple Sclerosis Based on Changes on Neurofilament Light Chain Z-Scores.

Neurology·2026

Predictors of Multiple Sclerosis After Clinically Isolated Syndrome: A Systematic Review and Meta-Analysis.

European journal of neurology·2026

Anti-CD20 associated enterovirus meningoencephalitis: A narrative review with two illustrative cases.

Multiple sclerosis journal - experimental, translational and clinical·2026

Rethinking prognosis in multiple sclerosis: a multiaxial perspective.

Nature reviews. Neurology·2026

Affective reserve in older adults with and without multiple sclerosis: A residual-based approach.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Persistent differences in initial diagnostic trajectory for Black and Hispanic individuals presenting with multiple sclerosis between 2020 and 2023.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Taking another look: LBSL diagnosed in adulthood masquerading as multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

A community-validated tool for clinical outcome calculation in multiple sclerosis: Consensus development and scenario-specific recommendations.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Implementation of a pilot online educational program to identify paramagnetic rim lesions.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Time-dependent divergence in infection risks among patients with multiple sclerosis treated with fumarates versus anti-CD20 monoclonal antibodies.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us